Introduction {#s1}
============

The prostanoids are part of a family of biologically active lipids derived from arachidonic acid which include the prostaglandins, prostacyclins and thromboxanes. Prostanoids are well-described primary mediators in pathological conditions such as inflammation, hypertension and cancer but are also essential for normal physiological function such as in the female reproductive system ([@GAQ094C33]). The importance of prostaglandins in the female reproductive tract is well documented in the mouse where targeted disruption of prostaglandin endoperoxidase synthase 1 or 2 (PTGS1 and PTGS2, previously known as COX1 and COX2) genes result in reduced reproductive efficiency ([@GAQ094C32]; [@GAQ094C21]). In humans, dysregulated endometrial prostanoid production has been described as a contributing factor in menstrual cycle disorders, infertility and uterine malignancies ([@GAQ094C23]; [@GAQ094C24]; [@GAQ094C2]). Non-steroidal anti-inflammatory drugs (NSAIDS) are well documented to inhibit prostanoid synthesis and are prominent analgesic/anti-inflammatory/antipyretic medication. However, a major drawback is that they target the early steps of biosynthesis thus blocking all prostanoids. Therefore, targeting of selective prostanoid synthases or receptors seem a logical progression in the development of new therapeutic strategies.

Prostanoids are not stored within cells, but are synthesized as required in response to stimuli. The first step in their synthesis is the release of arachidonic acid from the cellular phospholipids, by the action of the enzyme phospholipase A~2~. Arachidonic acid is converted by one of two related enzymes, PTGS1 and PTGS2, to form firstly prostaglandin PGG~2~ and subsequently reduced to prostaglandin PGH~2~. PGH~2~ is an unstable intermediate from which all other prostanoids are derived by a variety of different prostanoid synthases and isomerases (reviewed in [@GAQ094C59]; [@GAQ094C17]; summarized in Fig. [1](#GAQ094F1){ref-type="fig"}). Thus PGH~2~ is converted to PGD~2~, PGI~2~, TXA~2~ PGE~2~ and PGF~2α~ by prostaglandin D synthases (PTGDS and HPGDS), prostacyclin synthase (PTGIS) and thromboxane A synthase (TBXAS1), prostaglandin E synthases and prostaglandin F synthases, respectively. A number of distinct forms of prostaglandin E synthase exist, a membrane-bound type 1 (PTGES), a type 2 (PTGES2) which has various isoforms and a cytosolic (PTGES3) synthase. PGF~2α~ is synthesized via various routes, although not all routes of synthesis have been demonstrated in human endometrial cells. PGF~2α~ can be produced directly from PGH~2~ by aldo-keto reductase family 1 members B1 and C3 (AKR1B1 and AKR1C3). Alternatively, it can be synthesized via PGE~2~ by the action of the enzymes carbonyl reductase 1 (CBR1), AKR1C1 and AKR1C2 ([@GAQ094C56]; [@GAQ094C14]) or by reduction of PGD~2~ by AKR1C3. Prostanoids such as PGI~2~ and TXA~2~ are deactivated spontaneously before they are exported into the circulation as inactive metabolites. Other prostanoids, such as PGE~2~ and PGF~2α~, can be actively metabolized by hydroxyprostaglandin dehydrogenase (HPGD) or CBR1 into keto-prostanoids ([@GAQ094C7]; [@GAQ094C56]). Figure 1Prostanoid biosynthesis and signalling pathways. Arachidonic acid (AA) is converted by PTGS1 and PTGS2 to PGG~2~ and PGH~2~. PGH~2~ is then converted into one of the active prostanoids by specific terminal synthases such as PGE synthases (PTGES, PTGES2 and PTGES3), PGF synthases (AKR1B1 and AKR1C3), PGD synthases (PTGDS, HPGDS), PGI synthase (PTGIS) and thromboxane synthase (TBXAS1). PGE~2~ and PGF~2α~ may also be synthesized by interconversion by PGF~2α~ isomerases AKR1C1 and AKR1C2. PGF~2α~ may also be synthesized by conversion of PGD~2~ by AKR1C3 or PGE~2~ by CBR1. Synthesized prostanoids cross the plasma membrane via a carrier mediated process and bind to their respective cell surface receptors. Prostanoids may also be actively transported into the cytosol for degradation to inactive metabolites (PGEM and PGFM) by HPGD and CBR1. For abbreviations see Table [I](#GAQ094TB1){ref-type="table"}.

Following biosynthesis, prostanoids exert their function through G protein coupled receptors. The receptors have preferential binding to specific ligands; PTGER1--4 for PGE~2~, PTGFR for PGF~2α~, PTGDR1 and GPR44 for PGD~2~, PTGIR for PGI~2~ and TBXA2R for TXA~2~ ([@GAQ094C1]). Prostanoids may also exert their function through nuclear receptors such as binding of PGI~2~ to peroxisome proliferator-activated receptor (PPARδ) ([@GAQ094C15]).

The aim of this study was to identify the temporal expression profile of the prostanoid system in the human endometrium across the menstrual cycle. To our knowledge this is the first quantitative and fully comprehensive analysis of the prostanoid system across the menstrual cycle in the human endometrium. The data are discussed in relation to key inflammatory events during the menstrual cycle.

Materials and Methods {#s2}
=====================

Patients and tissue collection {#s2a}
------------------------------

Endometrial biopsies were obtained from women (age range 21--39 years) with regular menstrual cycles who had not received hormonal preparation in the 3 months preceding biopsy collection, and dated according to Noyes criteria ([@GAQ094C43]) by a pathologist. Circulating estradiol and progesterone concentrations were measured and were consistent with the histological assessment. Ethical approval was obtained from Lothian research ethics committee and written informed patient consent obtained before tissue collection.

Quantitative RT--PCR {#s2b}
--------------------

RNA was extracted with TRI-reagent (Thermo Scientific, Cramlington, UK) following manufacturers guidelines using phase lock tubes (Eppendorf, Cambridge, UK). RNA samples were reverse transcribed using MultiScribe (Applied Biosystems, Foster City, CA, USA) primed with random hexamers according to the manufacturer\'s instructions. PCR reactions were carried out using an ABI Prism 7500 (Applied Biosystems). Primer and FAM (6-carboxyfluorescein)-labelled probe sequences are shown in Table [I](#GAQ094TB1){ref-type="table"}. Multiple transcript variants have been reported for human PTGFR ([@GAQ094C30]). However, only the full length receptor was detected in the human endometrium in this study. Multiple transcript variants have been described for PTGER3 ([@GAQ094C27]), TBXA2R ([@GAQ094C38]) and TBXAS1 ([@GAQ094C53]). The primers utilized in this study did not distinguish between these isoforms. Pre-validated primers and probes were purchased for AKR1B1, PTGES3, HPGDS and GPR44 (Assay-on-Demand, Applied Biosystems). Primer-only amplification products were detected using SYBR Green (Applied Biosystems) incorporation during the PCR reaction. Gene expression was normalized to 18S ribosomal RNA (Applied Biosystems) as an internal standard. Results are expressed as relative to a standard (pooled endometrial tissue cDNA) included in all reactions. Table IQPCR primer and probe sequences.Gene symbolForward primerReverse primerProbePTGS1 (COX1), Prostaglandin-endoperoxidase synthase 1tgt tcg gtg tcc agt tcc aat aacc ttg aag gag tca ggc atg agcgc aac cgc att gcc atg gag tPTGS2 (COX2), Prostaglandin-endoperoxidase synthase 2cct tcc tcc tgt gcc tga tgaca atc tca ttt gaa tca gga agc ttgc ccg act ccc ttg ggt gtc aPTGES (mPGES1), Prostaglandin E synthasecgg agg ccc cca gta ttgggg tag atg gtc tcc atg tcg ttcga ccc gac gtg gaa cgPTGES2 (mPGES2) Prostaglandin E synthase 2cct cat cag caa gcg actcca ctt gtc agc agc ctc aagc agg cac cgc ctc cagPTGES3 (mPGES3), Prostaglandin E synthase 3Assay-on-Demand Hs01566250_gHAKR1B1, Aldo-keto reductase 1, member B1Assay-on-Demand Hs00739326_mlAKR1C3, Aldo-keto reductase 1, member C1ggg atc tca acg aga caa acgaaa gga ctg ggt cct cca agatgg acc cga act ccc cgg tgCBR1, Carbonyl reductase 1ctg atc cca cac cct ttc atgct cct cct cag tga tgg tcn/aPTGDS, Prostaglandin D2 synthasegct gca gga gaa tgg cta ctagg aag gtg gag gtc agg ttn/aHPGD (PDGH), Hydroxyprostaglandin dehydrogenasegtg aag gcg gca tca tta tctga atc caa cta tgc cat gcn/aPTGIS, Prostaglandin I2 (prostacyclin) synthaseacg cag atg tgg aga tcc ctgtc gtg ttc cgg ctg cacct cag cag gta cgg ctt cgg tct gTBXAS1, Thromboxane A synthase 1cag gtg ttg gtt gag aac ttc agt atgt cgg cta ccg act tga actcaa acc cga cgc cat tct gtt ggt aaa gHPGDS, Haematopoietic prostaglandin D synthaseAssay-on-Demand IDHs00183950_mlPTGER1, Prostaglandin E receptor 1aga tgg tgg gcc agc ttg tgcc acc aac acc agc att gcag cag atg cac gac acc acc atgPTGER2, Prostaglandin E receptor 2gac cgc tta cct gca gct gta ctga agt tgc agg cga gcacca ccc tgc tgc tgc ttc tca ttg tctPTGER3, Prostaglandin E receptor 3gac ggc cat tca gct tat ggttg aag atc att ttc aac atc att atc actg tcg gtc tgc tgg tct ccg ctcPTGER4, Prostaglandin E receptor 4acg ccg cct act cct aca tgaga gga cgg tgg cga gaa tacg cgg gct tca gct cct tcc tPTGFR, Prostaglandin F receptorgca gct gcg ctt ctt tca acac tgt cat gaa gat tac tga aaa aaa taccac aac ctg cca gac gga aaa ccgPTGDR, Prostaglandin D2 receptortga tga ccg tgc tct tca ctcac cgg ctc ctg tac cta agn/aGPR44 (CRTH2), G protein-coupled receptor 44Assay-on-Demand, IDHs00173717_mlPTGIR, Prostaglandin I2 receptorgcc ctc ccc ctc tac caattt tcc aat aac tgt ggt ttt tgt gcca aga gcc agc ccc ctt tct gcTBXA2R, Thromboxane A2 receptortgg tgg tgg cca gcg tcgg gtt tcg cag cac tgttgc ccc ttc tgg tct tca tcg ccc

Immunohistochemistry {#s2c}
--------------------

Five micrometres of paraffin-embedded sections were de-waxed and rehydrated through graded alcohols before antigen retrieval was carried out using 0.01 M citrate phosphate buffer in a pressure cooker for 5 min at maximum pressure. After release of pressure, the sections were incubated for a further 21 min before endogenous peroxidase activity was blocked by 5 min incubation in 3% solution of hydrogen peroxide: methanol. Immunohistochemistry was performed using an automated Visions Biosytems 'Bond' Immunohistochemistry system (Bond, CA, USA). Sections were incubated for 120 min with primary antibodies such as mouse anti-AKR1C3 (1:5000; A6229; Sigma, Dorset, UK); rabbit anti-AKR1B1 (1:50; Ab71405; Abcam, Cambridge, UK); goat anti-CBR1 (1:500; Ab4148; Abcam); rabbit anti-PTGDR (1:100; 101640; Cayman Chemicals, Ann Arbor, MI, USA); rabbit anti-PTGER1 (1:500; 101740; Cayman Chemicals) and a corresponding post-primary protocol. Sections were then counterstained in haematoxylin and mounted in pertex. Sections were imaged using a Provis AX70 microscope (Olympus, Southend-on-Sea, UK) and photographed using an AxioCam HRc with AxioVision Release 4.8 (Carl Zeiss Ltd, Berlin, Germany). Immunohistochemistry was performed in duplicate on three to five different endometrial samples for each phase of the menstrual cycle and the most representative section was imaged.

Statistics {#s2d}
----------

Data were subjected to statistical analysis using a one-way analysis of variance with Tukey\'s multiple comparison post test (GraphPad Prism, GraphPad Software, Inc., La Jolla, CA, USA).

Results {#s3}
=======

RNA transcript expression of prostanoid enzymes across the menstrual cycle {#s3a}
--------------------------------------------------------------------------

Quantitative real-time PCR (Q-RT--PCR) was performed to determine the RNA transcriptional profiles of prostanoid enzymes in endometrial tissue collected across the menstrual cycle. The temporal pattern of expression for all synthase enzymes is illustrated in Fig. [2](#GAQ094F2){ref-type="fig"}. The analyses demonstrate that expression of prostanoid synthases are predominantly elevated in the secretory and menstrual phases of the cycle with a decrease in expression in the proliferative phase (Fig. [2](#GAQ094F2){ref-type="fig"} and Table [II](#GAQ094TB2){ref-type="table"}). Table IISummary of significant increases in expression of prostanoid enzymes across the menstrual cycle; menstrual (Mn), proliferative (P), early secretory (ES), mid-secretory (MS) and late secretory phase (LS).Comparison*P-*valueMean fold increasePTGS1 MS versus P*P* \< 0.0510.5 MS versus LS*P* \< 0.0115.5PTGS2 Mn versus P*P* \< 0.0116.5 Mn versus MS*P* \< 0.018.9 Mn versus LS*P* \< 0.0112.9PTGES LS versus P*P* \< 0.0016.9 LS versus ES*P* \< 0.0019.6 LS versus MS*P* \< 0.013.3PTGES2 MS versus LS*P* \< 0.053.5PTGES3 ES versus P*P* \< 0.052.4 ES versus LS*P* \< 0.0014.9 MS versus P*P* \< 0.052.4 MS versus LS*P* \< 0.014.8 Mn versus P*P* \< 0.0018.5 Mn versus ES*P* \< 0.0013.5 Mn versus MS*P* \< 0.0013.6 Mn versus LS*P* \< 0.00117.1AKR1B1 Mn versus P*P* \< 0.0013.2 Mn versus ES*P* \< 0.012.6 Mn versus MS*P* \< 0.052 Mn versus LS*P* \< 0.052AKR1C3 ES versus P*P* \< 0.0015.5 ES versus MS*P* \< 0.012.2 ES versus LS*P* \< 0.0013.7 ES versus Mn*P* \< 0.052.4CBR1 Mn versus P*P* \< 0.00110.7 Mn versus ES*P* \< 0.0016.6 Mn versus MS*P* \< 0.015.2 Mn versus LS*P* \< 0.052.4HPGDS MS versus Mn*P* \< 0.015.9 MS versus P*P* \< 0.00111.1 LS versus Mn*P* \< 0.016.7 LS versus P*P* \< 0.00112.6 LS versus ES*P* \< 0.052.5PTGDS MS versus P*P* \< 0.058.9 MS versus Mn*P* \< 0.0536.6PTGIS LS versus P*P* \< 0.0019.4 LS versus ES*P* \< 0.0015.6 LS versus MS*P* \< 0.012.4 LS versus Mn*P* \< 0.013.3TBXAS1 MS versus P*P* \< 0.0016.1 MS versus ES*P* \< 0.0015.7 MS versus LS*P* \< 0.052.2HPGD ES versus P*P* \< 0.059.9 ES versus LS*P* \< 0.0512.6 Figure 2QPCR expression analysis of prostanoid enzymes across the menstrual cycle. Relative levels of RNA transcripts were quantified by RT--PCR from endometrial samples taken from the menstrual (Mn), proliferative (P), early secretory (ES), mid-secretory (MS) and late secretory (LS) phase of the menstrual cycle. Expression levels were measured compared with a calibrator RNA sample. The graphs show individual values for each sample, mean expression levels in arbitrary units normalized to 18S ribosomal RNA and error bars represent SEM. Mn (*n* = 5), P (*n* = 10), ES (*n* = 10), MS (*n* = 10) and LS (*n* = 10); Different letters (a--c) represent statistically significant differences between groups (see Table [II](#GAQ094TB2){ref-type="table"} for *P*-values); ns, not significant.

Significant mean fold increases in expression across the menstrual cycle for each prostanoid enzyme are shown in Table [II](#GAQ094TB2){ref-type="table"}. The table illustrates that expression for all prostanoid synthases, except PTGES2, during the menstrual phase is higher by 2-fold or more compared with the proliferative phase. A 10-fold or more increase in expression was observed for PTGS1 (15.5-fold, MS versus LS), PTGS2 (16.5-fold, Mn versus P), PTGES3 (17.1-fold, Mn versus LS), CBR1 (10.7-fold, Mn versus P), HPGDS (12.6-fold, LS versus P) and PTGDS (36.6-fold, MS versus Mn). The expression of HPGD, a regulator of prostanoid catabolism, was significantly decreased in the proliferative and late secretory phases.

RNA transcript expression of prostanoid receptors across the menstrual cycle {#s3b}
----------------------------------------------------------------------------

Q-RT--PCR was performed to determine the RNA transcriptional profiles of prostanoid receptors in endometrial tissue collected across the menstrual cycle. The temporal pattern of expression for prostanoid receptors is illustrated in Fig. [3](#GAQ094F3){ref-type="fig"}. The analysis demonstrated that expression of the prostanoid receptors are predominantly elevated in the secretory phase of the cycle except for the expression of PTGFR which is significantly elevated in the proliferative phase (Fig. [3](#GAQ094F3){ref-type="fig"} and Table [III](#GAQ094TB3){ref-type="table"}). Table IIISummary of significant increases in expression of prostanoid receptors across the menstrual cycle; menstrual (Mn), proliferative (P), early secretory (ES), mid-secretory (MS) and late secretory phase (LS).Comparison*P*-valueMean fold increasePTGER1 ES versus LS*P* \< 0.0013.8 ES versus Mn*P* \< 0.00112.2PTGER2 MS versus P*P* \< 0.00115.1 MS versus ES*P* \< 0.0017.3 MS versus LS*P* \< 0.0012.6 MS versus Mn*P* \< 0.0017PTGER3 MS versus P*P* \< 0.052.2 MS versus ES*P* \< 0.012.4 MS versus LS*P* \< 0.052.3 MS versus Mn*P* \< 0.052.9PTGER4 MS versus P*P* \< 0.0012.2 MS versus ES*P* \< 0.0012.4 MS versus Mn*P* \< 0.011.9 LS versus ES*P* \< 0.051.9PTGFR P versus LS*P* \< 0.015.8 P versus Mn*P* \< 0.0510.3PTGDR LS versus ES*P* \< 0.059PTGIR LS versus P*P* \< 0.00122.3 LS versus ES*P* \< 0.00111.1 LS versus MS*P* \< 0.016.8TBXA2R ES versus Mn*P* \< 0.059.4 MS versus Mn*P* \< 0.00113 LS versus Mn*P* \< 0.00112.7 Figure 3QPCR expression analysis of prostanoid receptors across the menstrual cycle. Relative levels of RNA transcripts were quantified by RT--PCR from endometrial samples taken from the menstrual (Mn), proliferative (P), early secretory (ES), mid-secretory (MS) and late secretory (LS) phase of the menstrual cycle. Expression levels were measured compared with a calibrator RNA sample. The graphs show individual values for each sample, mean expression levels in arbitrary units normalized to 18S ribosomal RNA and error bars represent SEM. Mn (*n* = 5), P (*n* = 10), ES (*n* = 10), MS (*n* = 10) and LS (*n* = 10); Different letters (a--c) represent statistically significant differences between groups (see Table [III](#GAQ094TB3){ref-type="table"} for P-values); ns, not significant.

The significant mean fold increase in expression across the menstrual cycle for each prostanoid receptor is shown in Table [III](#GAQ094TB3){ref-type="table"}. A dramatic increase in expression is observed in the proliferative phase for PTGFR (10.3-fold, P versus Mn), in the early secretory phase for PTGER1 (12.2-fold, ES versus Mn), in the mid-secretory phase for PTGER2 (15.1-fold, MS versus P) and TBXR (13.0-fold, MS versus Mn) and in the late secretory phase for PTGIR (22.3-fold, LS versus P) and PTGDR (9.0-fold LS versus ES).

Immunohistochemical localization of prostanoid enzymes and receptors in the human endometrium {#s3c}
---------------------------------------------------------------------------------------------

Immunohistochemical analysis was performed for selected genes which have not been studied previously in the human endometrium across the menstrual cycle. These included AKR1C3, CBR1, AKR1B1, PTGDR and PTGER1. The analysis aimed to determine whether the RNA transcripts detected by Q-RT--PCR were translated into protein products and to determine their spatial and temporal expression across the menstrual cycle. All transcripts detected by RT--PCR were shown to be translated into protein products (Fig. [4](#GAQ094F4){ref-type="fig"}). The staining intensity of the immunohistochemistry suggested protein expression was comparable to RNA expression obtained by Q-RT--PCR except for staining of AKR1C3 and AKR1B1 in the mid-secretory phase and PTGER1 in the proliferative phase. These differences suggested a modest decrease in protein expression compared with the RNA expression profile, although caution must be exercised when interpreting immunohistochemistry. Quantitatively interpreting immunostaining between a section with intense localized staining and a section with moderate staining intensity throughout may give a misleading impression of differences in global expression levels. Figure 4Immunohistochemical localization of AKR1C3 (**A**--**E**), CBR1 (**F**--**J**), AKR1B1 (**K**--**O**), PTGDR (**P**--**T**) and PTGER1 (**U**--**Y**) in the endometrium across the menstrual cycle; proliferative endometrium (A, F, K, P, U), early-secretory endometrium (B, G, L, Q, V), mid-secretory endometrium (C, H, M, R, W), late secretory endometrium (D, I, N, S, X) and menstrual endometrium (E, J, O, T, Y). Negative controls (−ve). For abbreviations see Table [I](#GAQ094TB1){ref-type="table"}.

AKR1C3 immunostaining was localized to the glandular and luminal epithelium and the blood vessels (Fig. [4](#GAQ094F4){ref-type="fig"}A--E). Immunostaining was very prominent throughout the cycle, and in the menstrual phase (Fig. [4](#GAQ094F4){ref-type="fig"}E) staining in the blood vessels became more prominent. CBR1 immunostaining was localized predominantly to the glandular and luminal epithelium (Fig. [4](#GAQ094F4){ref-type="fig"}F--J). Staining was observed in the stroma throughout the menstrual cycle but was faint and inconsistent. AKR1B1 immunostaining was localized predominantly to the glandular and luminal epithelium and the blood vessels with less intense and scattered stromal perinuclear staining (Fig. [4](#GAQ094F4){ref-type="fig"}K--O). In the late secretory phase and menstrual phase (Fig. [4](#GAQ094F4){ref-type="fig"}N and O) immunostaining was observed in a subset of stromal cells. PTGDR immunostaining was localized to the glandular epithelium, blood vessels and throughout the stroma but not to all cells (Fig. [4](#GAQ094F4){ref-type="fig"}P--T). Intense immunostaining was observed in aggregating cells in the stroma in the secretory phase and menstrual phase (Fig. [4](#GAQ094F4){ref-type="fig"}S and T). PTGER1 was shown to be localized to the glandular epithelium. Immunostaining of proliferative phase and early secretory phase (Fig. [4](#GAQ094F4){ref-type="fig"}U and V) endometrium was weak and confined to the nuclear region. In the mid- and late secretory phases (Fig. [4](#GAQ094F4){ref-type="fig"}W--X) immunostaining was intense and localized predominantly to the apical membrane of the glandular epithelium. Menstrual phase immunostaining was faint and localized to the nuclear region of the glandular epithelium (Fig. [4](#GAQ094F4){ref-type="fig"}Y).

Discussion {#s4}
==========

Inflammatory events have been described in the human endometrium during the period of endometrial receptivity and menstruation. These events are characterized by an increase in endometrial capillary dilation, permeability, stromal edema, blood flow, leucocyte number and secretion of pro-inflammatory factors ([@GAQ094C18]; [@GAQ094C25]; [@GAQ094C45]). Pro-inflammatory enzymes PTGS1 and PTGS2 are key mediators of these inflammatory processes. However, the downstream prostanoids and receptors that contribute to these inflammatory events remain unclear. The aim of this study was to provide expression profiles across the menstrual cycle of the genes which constitute the prostanoid biosynthetic and signalling pathways. The data generated in this study are summarized in Fig. [5](#GAQ094F5){ref-type="fig"} and indicate the stage of the menstrual cycle where maximum transcript expression occurs for each gene. The data suggest that distinct components of the prostanoid system are associated with specific stages of the menstrual cycle and expression predominantly increases from the mid-secretory phase through to, and including, menstruation. Figure 5Expression of prostanoid biosynthetic enzyme and receptor genes in the menstrual cycle. Summary diagram illustrating the maximal expression during the menstrual cycle for each prostanoid biosynthesis and receptor gene analysed and reported maximum production during the menstrual cycle for each prostanoid (shown in red). WOI, window of implantation. For abbreviations see Table [I](#GAQ094TB1){ref-type="table"}.

The proliferative phase of the menstrual cycle is characterized by endometrial re-growth consisting of endometrial cell proliferation and angiogenesis. This study confirms that the expression of PTGFR is maximal during the proliferative phase ([@GAQ094C39]) and therefore distinct to other components of the prostanoid biosynthetic and signalling pathway. PTGFR is predominantly expressed in the glandular epithelium and also the stromal and perivascular cells ([@GAQ094C39]). PGF~2α~ signalling via PTGFR in endometrial epithelial cells has been shown to induce changes in epithelial cell morphology and migration ([@GAQ094C50]), proliferation ([@GAQ094C49]) and angiogenesis ([@GAQ094C26]) suggesting an important role for this receptor in tissue remodelling during endometrial re-growth. PGF~2α~ production in the endometrium has been shown to rise significantly in the mid-proliferative phase ([@GAQ094C13]). This increase may be due to the reduction of HPGD expression at this time which would reduce PGF~2α~ degradation.

The secretory phase is dependent on the rise in progesterone secretion following ovulation and induces endometrial differentiation. During the secretory phase prostanoid production continues to increase ([@GAQ094C13]), which can be accounted for by the elevated expression of PTGS1 increasing the availability of PGH~2~ for enzymatic conversion. During the early secretory phase PTGER1 expression is maximal. PTGER1 has been reported to be expressed strongly in the luminal and glandular epithelium ([@GAQ094C6]). We demonstrate that PTGER1 immunostaining in the proliferative, early secretory and menstrual phases is localized to the nuclear region of the glands similar to reports for PGE~2~ receptors 3 and 4 ([@GAQ094C4]) and during the mid- and late secretory phases localizes to the apical plasma membrane of the glands. This suggests that PTGER1 may have two distinct functions in the endometrium depending on its localization. The expression of the prostanoid receptors PTGER2, 3 and 4 peaked during the mid-secretory phase. The increased expression of these receptors coincides with increased stromal oedema, blood vessel permeability and endometrial blood flow in the human endometrium ([@GAQ094C18]; [@GAQ094C25]; [@GAQ094C45]). Evidence supporting a role for PGE~2~ receptors in these events is demonstrated by infusion of PGE~2~ into rodent uteri which has been shown to increase uterine vascular permeability, uterine extracellular fluid volume ([@GAQ094C22]) and act as an immunomodulator inhibiting lytic activation of maternal leucocytes ([@GAQ094C44]).

Endometrial PGD~2~ release has been shown to peak during the mid-secretory phase ([@GAQ094C47]) and is produced by macrophages and glandular epithelial cells ([@GAQ094C42]; [@GAQ094C41]). Two PGD~2~ synthases have been characterized: lipocalin type (PTGDS) ([@GAQ094C55]) and haematopoietic PGDS (HPGDS). The peak in PTGDS expression in the mid-secretory phase supports data demonstrating PTGDS to be regulated by progesterone, as expression decreases in the endometrium after administration of mifepristone ([@GAQ094C8]). The expression of HPGDS also peaked in the mid-secretory phase and was maintained throughout the late secretory phase. PGD~2~ is involved in multiple aspects of inflammation through its dual receptor systems, PTGDR and GPR44 (previously known as CRTH2). GPR44 is a chemo-attractant receptor expressed on T-helper (Th) and T-cytotoxic (Tc) 2 cells, eosinophils and basophils ([@GAQ094C40]; [@GAQ094C57]). PTGDR expressed on dendritic cells has been shown to inhibit T cell migration ([@GAQ094C20]). In the endometrium PGD~2~ through its two receptors regulates recruitment of Th2 and Tc2 cells into the implantation site ([@GAQ094C37]) and positively regulates trophoblast invasion ([@GAQ094C10]). GPR44 expression levels were low and did not change throughout the menstrual cycle, whereas PTGDR expression increased from the mid-secretory to the menstrual phase. Immunostaining of PTGDR during the late secretory phase and menstrual phase was detected in cell aggregates in the stroma. This observation may reflect the influx of immune cells into the endometrium at these stages ([@GAQ094C48]) as dentritic cells, macrophages and natural killer cells have been shown to express PTGDR ([@GAQ094C12]; [@GAQ094C54]). Immunostaining for PTGDR also localized to the blood vessels. This suggests PGD~2~ may regulate menstrual blood loss during menstruation via known functions of PGD~2~ on platelets and blood vessels, such as increasing blood flow and inhibiting platelet aggregation and smooth muscle contraction and relaxation ([@GAQ094C5]; [@GAQ094C16]).

Our data also demonstrate a role for thromboxane during the secretory phase. TBXAS1 expression peaked during the mid-secretory phase and TBXA2R expression was elevated throughout the secretory phase. TXA~2~ is classically known to cause platelet aggregation and constriction of blood vessels and in the endometrium presumed to regulate blood flow ([@GAQ094C53]). TXA~2~ has also been described to have other functions such as the regulation of angiogenesis, but this has not been investigated in the endometrium ([@GAQ094C9]). TBXAS1 immunostaining has been observed in glandular epithelium, stroma and blood vessels and increased in the glandular epithelium during the secretory phase ([@GAQ094C53]).

In the late secretory phase in a non-pregnant cycle the corpus luteum involutes and progesterone levels decline, triggering menstruation. The menstrual phase is characterized by ischaemia due to vasoconstriction of endometrial vessels, rupture of the capillaries initiating bleeding and the consequent shedding of the functional layer of the endometrium. During the late secretory and menstrual phases PGF~2α~, PGE~2~, TXA~2~ and PGI~2~ production rises significantly ([@GAQ094C13]; [@GAQ094C31]; [@GAQ094C19]). Our results from the expression analysis of the prostanoid enzymes provide data on how the production of PGF~2α~ and PGE~2~ are regulated. The production of PGE~2~ is regulated by different synthases predominating during the menstrual cycle with PTGES2 during the mid-secretory phase, PTGES during the late secretory phase and PTGES3 during the menstrual phase. This may reflect a mechanism by which PGE~2~ production in the endometrium may be maintained under different regulatory conditions. Classically the role of PGF~2α~ via PTGFR during the menstrual stage is to mediate vasoconstriction of the endometrial vessels and contraction of the smooth muscles of the myometrium. Evidence supporting the functionality of the potential PGF~2α~ synthases (AKR1B1, AKR1C1, AKR1C2, AKR1C3 and CBR1) in the human endometrium has only been demonstrated for AKR1B1 ([@GAQ094C11]), AKR1C3 and CBR1 ([@GAQ094C28]; [@GAQ094C46]) therefore only these genes were analysed in this study. The rise in both PGF~2α~ and PGE~2~ menstrually reflects the significant increase in PTGS2 and the terminal prostanoid synthases AKR1B1, CBR1 and PTGES3. The immuno-localization of CBR1, AKR1C3 and AKR1B1 are predominantly in the glandular epithelium and vasculature of the endometrium. This is in agreement with previous studies which report glandular epithelial cells to produce more PGF~2α~ than stromal cells ([@GAQ094C34]). AKR1C3 immunoreactivity has previously been shown in the luminal and glandular epithelium ([@GAQ094C46]). We also demonstrate AKR1B1 immunoreactivity in a subset of stromal cells in the late and menstrual phases. Immunostaining for AKR1B1 localized to the perinuclear region in stromal cells. Terminal prostanoid synthases show distinct functional coupling with upstream COX isoxymes ([@GAQ094C58]). The immunostaining supports previous data ([@GAQ094C11]) suggesting that AKR1B1 couples to PTGS2 which resides predominantly in the perinuclear membranes.

PGI~2~ is the main prostanoid synthesized by the vascular endothelium and it causes blood vessel dilatation and inhibition of platelet aggregation ([@GAQ094C52]): these effects have suggested a role for PGI~2~ in menstruation. PTGIS and PTGIR immunoreactivity in the endometrium is localized predominantly to the glandular and luminal epithelium with expression also detected in the vasculature and stroma ([@GAQ094C3]). PGI~2~ has been shown to be inhibited by progesterone ([@GAQ094C29]) which correlates with the expression of PGIS peaking in the late secretory phase as progesterone is withdrawn. PTGIR with a similar expression profile has also been demonstrated to be inhibited by progesterone as expression increases in the endometrium after administration of mifepristone ([@GAQ094C8]).

This study represents the first comprehensive view of prostanoid action in the endometrium during the menstrual cycle. Identifying the expression profile of the prostanoid system and its association to key inflammatory events provides valuable insight into the role of specific signalling pathways in normal endometrial function. Menstrual cycle disorders such as primary dysmenorrhea and heavy menstrual blood loss in the absence of any pathology have been associated with an increase and an imbalance in prostanoid synthesis ([@GAQ094C35]; [@GAQ094C51]; [@GAQ094C36]). Hence the data presented herein provides the potential to identify which component(s) of the prostanoid system may contribute to inflammatory-associated disorders of the endometrium such as heavy menstrual blood loss and dysmenorrhoea and may aid in the development of novel therapeutics.
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